HormoneFDA Approved

Tesamorelin (Egrifta)

Subcutaneous injection (daily)

Overview

A synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability. Tesamorelin specifically targets visceral adipose tissue reduction by stimulating lipolysis through GH-mediated pathways.

Mechanism of Action

It is the only FDA-approved treatment for HIV-associated lipodystrophy..

Research Summary & Key Findings

FDA-approved in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Clinical trials showed 15-18% reduction in visceral adipose tissue. Also demonstrated improvements in liver fat content in patients with NAFLD in Phase 2 studies.

Clinical Status

FDA Approved

Tesamorelin (Egrifta) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Subcutaneous injection (daily)

Related Peptides in Hormone

CJC-1295

In Clinical Trials

A synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, ...

View details

Ipamorelin

In Clinical Trials

A highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH...

View details

Sermorelin

FDA Approved

A synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid...

View details

PT-141 (Bremelanotide / Vyleesi)

FDA Approved

A synthetic cyclic heptapeptide melanocortin receptor agonist that activates MC3R and MC4R in the central nervous system...

View details

Find a Provider

Find a verified provider who offers Tesamorelin (Egrifta) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Tesamorelin (Egrifta).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.